Charles Schwab’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Charles Schwab’s Portfolio ETTX Stock Details ETTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-14,236	Closed	-$32K	–	3602
2022 Q2	$32K	Buy	+14,236	New	+$28.4K	﹤0.01%	3463

Charles Schwab's ETTX Position: Q3 2022 in Review

Charles Schwab sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q3 2022, closing a stake of 14,236 shares — an estimated $32K sold.

Charles Schwab first reported a position in ETTX in Q2 2022 and held it in 1 quarter. The position peaked at $32K in Q2 2022. 0 funds tracked by Wall St. Rank hold ETTX as of Q3 2022.

Charles Schwab reported no remaining Entasis Therapeutics Holdings Inc. position as of Q3 2022 after selling out during the quarter.
Charles Schwab sold 14,236 Entasis Therapeutics Holdings Inc. shares in Q3 2022, an estimated $32K.
Charles Schwab first reported a position in Entasis Therapeutics Holdings Inc. in Q2 2022 and held it in 1 quarter.
Charles Schwab's Entasis Therapeutics Holdings Inc. position peaked at $32K in Q2 2022.
0 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q3 2022.

Based on Charles Schwab's 13F filing for Q3 2022, filed 14 Nov 2022.